Amelia Langston, MD
Medical Oncology · Atlanta, GANPI 1346357019
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (44.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Modernatx, Inc. at 44.9% of the total. 2024 is the largest year on record at $2,636, 8.8 times the $298 reported in 2019. That places this record below the midpoint for medical oncology clinicians in GA, where the typical reported total is $5,509.
Across 22 payments — averaging $250.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Modernatx, Inc.$2K
- Genentech USA, Inc.$1K
- National Marrow Donor Program$986
- Novartis$360
- Astellas Pharma US Inc$191
- Gilead$94
- plus $22 from 1 others
Across 281 payments — averaging $7382.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Jazz Pharmaceuticals Inc.$965K
- Incyte Corporation$335K
- Takeda Pharmaceuticals U.S.A., Inc.$302K
- AbbVie$232K
- CSL Behring$105K
- National Marrow Donor Program$80K
- plus $55K from 5 others
What the payments were for
- Consulting fees$2,47545%
- Travel & lodging$1,11920%
- Food & beverage$1,70131%
- Education$2134%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Modernatx, Inc. | 5 | $2,475 |
| Genentech USA, Inc. | 4 | $1,380 |
| National Marrow Donor Program | 2 | $986 |
| Novartis | 6 | $360 |
| Astellas Pharma US Inc | 2 | $191 |
| Gilead | 2 | $94 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KYMRIAH$121
How this compares
$5,509 in reported general payments places this provider in the 50th percentile of 68 medical oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 99 | $1,519,443 |
| RezurockBelumosudil Mesylate | 51 | $1,424,002 |
| IclusigPonatinib Hcl | 17 | $446,143 |
| ImbruvicaIbrutinib | 25 | $379,658 |
| TibsovoIvosidenib | 11 | $371,114 |
| PrevymisLetermovir | 43 | $306,643 |
| PomalystPomalidomide | 11 | $234,893 |
| CresembaIsavuconazonium Sulfate | 15 | $89,248 |
| VenclextaVenetoclax | 15 | $81,780 |
| EliquisApixaban | 11 | $8,499 |
| Sirolimus | 11 | $2,756 |
| ValacyclovirValacyclovir Hcl | 73 | $2,374 |
| Fluconazole | 30 | $2,242 |
| Acyclovir | 46 | $1,497 |
| Tacrolimus | 15 | $912 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Iclusig | $22 | $446,14317 claims |
| Astellas Pharma US IncCresemba | $191 | $89,24815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 68 medical oncology providers in Georgia.
Other medical oncology in Atlanta
- Nabil SabaAtlanta$225K
- Suresh RamalingamAtlanta$75K
- Jonathan KaufmanAtlanta$73K
- Ragini KudchadkarAtlanta$69K
- Nisha JosephAtlanta$50K
- Eyal MeiriAtlanta$39K
- Erin DunbarAtlanta$35K
- Olumide GbolahanAtlanta$32K
- Bradley CarthonAtlanta$31K
- Joseph MaakaronAtlanta$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.